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Abstract Splicing enhancers have previously been shown to
promote processing of introns containing weak splicing signals.
Here, we extend these studies by showing that also ‘strong’
constitutively active introns are absolutely dependent on a
downstream splicing enhancer for activity in vitro. SR protein
binding to exonic enhancer elements or U1 snRNP binding to a
downstream 5P splice site serve redundant functions as activators
of splicing. We further show that a 5P splice site is most effective
as an enhancer of splicing. Thus, a 5P splice site is functional in
S100 extracts, under conditions where a SR enhancer is non-
functional. Also, splice site pairing occurs efficiently in the
absence of exonic SR enhancers, emphasizing the significance of
a downstream 5P splice site as the enhancer element in vertebrate
splicing.
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1. Introduction
Numerous studies have shown that splicing of pre-mRNAs
containing weak 3P splice sites, i.e. splice sites that do not
conform to the 3P splice site consensus sequence, requires
splicing enhancer elements for activity (reviewed in [1^3]).
Enhancer-dependent introns typically contain short polypyri-
midine tracts that bind U2AF ine⁄ciently and, thus, require
auxiliary factors for the e⁄cient recruitment of U2AF to the
3P splice site. Inclusion of such exons is often subjected to
regulation and has therefore been subjected to an intensive
study. Splicing enhancers are usually located in the exon
downstream of the a¡ected intron. Exonic splicing enhancers
typically bind members of the SR family of splicing factors
(reviewed in [1,2]). However, U1 snRNP binding to a down-
stream 5P splice site also functions as an enhancer, stimulating
upstream intron removal, the so called exon de¢nition model
[4,5].
Here, we show that in vitro splicing of two constitutively
active introns, the adenovirus 52,55K and Drosophila fushi
tarazu (Ftz) introns, both require a downstream enhancer
for activity. Our results show that SR proteins binding to
an exonic splicing enhancer or U1 snRNP binding to a down-
stream 5P splice site individually function as splicing enhancer
factors activating the upstream intron removal. In fact, an
exon with a downstream 5P splice site obviates the need for
an exonic SR binding splicing enhancer. Our results further
suggest that a 5P splice site is more e¡ective compared to a SR
enhancer in activating splicing. Thus, a 5P splice site activates
splicing in S100 extracts under conditions where a SR en-
hancer is non-functional. Collectively, our results lend further
support for the model that initial pairing of a splice site pref-
erentially occurs across the exon (the exon de¢nition model
[4,5]).
2. Materials and methods
2.1. Plasmids and transcript synthesis
Plasmids pGem2 V61 (here referred to as Ftz), IIIa and 52,55K
have previously been described [6,7]. By PCR cloning the 49 nucleo-
tide 3RE [8], a 28 nucleotide long, duplicated ASF/SF2 enhancer [8,9]
or the 49 nucleotide L-globin enhancer minus sequence [8] was ap-
pended six nucleotides downstream of the 52,55K 3P splice site, gen-
erating plasmids mini52,55K,3a (3RE), mini52,55K,3a (2ASF) and
mini52,55K,3a (33RE), respectively. Plasmid miniFtz,3a (33RE)
was generated by replacing the 52,55K ¢rst exon and intron with
the corresponding sequence from pGem2-V61. All pre-mRNAs were
transcribed with T7 RNA polymerase from PCR-ampli¢ed products,
with or without a 5P splice site appended at the 3P end [10]. Suitable
double-stranded DNA templates for in vitro transcription were gen-
erated by using appropriately designed oligonucleotides in PCR reac-
tions [10]. Plasmid maps, DNA sequences and the composition of
primer pairs are available on request or at www.bmc.uu.se/IMIM/
res/GA.html.
2.2. Extract preparation and in vitro splicing
HeLa nuclear extract was prepared as previously described [6]. The
cytoplasmic fraction was saved and used to prepare splicing de¢cient
S100 extracts as described [11]. Nuclear extracts were fractionated by
three steps of ammonium sulfate precipitation (ASP) to obtain the 40,
60 and 90 ASP fractions as previously described [12]. All fractions
were dialyzed against bu¡er D [13]. The total splicing reaction volume
was 25 Wl and contained 5^25 fmol 32P-labelled transcript, 10 Wl nu-
clear or S100 extracts, 5 Wl bu¡er D, extract fractions or HeLa SR
proteins (0.5 Wg), 2.6% polyvinylic alcohol, 12% glycerol, 12 mM
HEPES (pH 7.9), 60 mM KCl, 2 mM ATP, 20 mM creatine phos-
phate, 0.3 mM DTT, 2.5 mM MgCl2 and 15 U RNasin. Reactions
were incubated at 30‡C, for 2 h. Splicing products were resolved on
denaturing 8% polyacrylamide gels, followed by autoradiography.
2.3. U snRNA depletion
Oligonucleotide-directed RNase H cleavage of U snRNPs in the 40
ASP was done exactly as described [14]. An aliquot of the cleaved
extract was used to verify that the RNase H treatment e¡ectively
destroyed the designated U snRNA, the remaining of the extract
was used for a splicing assay. Oligonucleotides 5PC and E15 [15]
directed against the 5P ends of U1 snRNA and U2 snRNA were
used in the depletion reaction.
2.4. Western blot analysis
10 Wl of 40, 60 and 90 ASP were separated by 12% SDS-PAGE
under reducing conditions. Proteins were transferred to a nitrocellu-
lose membrane by electroblotting. The membrane was blocked in TBS
bu¡er (50 mM Tris pH 7.5, 150 mM NaCl, 0.1% Tween-20) contain-
ing 5% non-fat dry milk (w/v), washed in TBS and incubated with
monoclonal antibody 2.73 ([16] 1:100 dilution in TBS) for 1 h with
gentle shaking at room temperature. The membrane was washed three
times in TBS, incubated with anti-mouse antibody conjugated with
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horseradish peroxidase (Amersham, diluted 1:5000 in TBS) for 1 h at
room temperature, followed by three washes with TBS, each for 10
min. Proteins were visualized by chemiluminescence as described in
the manufacturer’s protocol (Amersham).
3. Results
Here, we have tested the signi¢cance of U1 snRNP and SR
proteins as splicing enhancer factors. Splicing de¢cient S100
extracts contain low amounts of SR proteins, below the
threshold concentration required to activate splicing [11].
Thus, by complementing S100 extracts with puri¢ed SR pro-
teins or fractions enriched in U1 snRNP, the signi¢cance of a
respective factor for splicing activation was tested.
In most of these studies, we used the adenovirus major late
region 1 52,55K and IIIa introns as model substrates for
strong and weak 3P splice sites, respectively. The constitutively
active 52,55K intron contains a prototypical 3P splice site with
a high pyrimidine content (18 pyrimidines out of 19 nucleo-
tides), whereas the regulated IIIa intron is weak with a short
polypyrimidine tract frequently interrupted by purines [6].
3.1. An U1 enhancer activates IIIa intron splicing
Appending the strong adenovirus major late ¢rst leader 5P
splice site [10] (we refer to this as an U1 enhancer) to the weak
adenovirus IIIa second exon resulted in a 20^50-fold stimula-
tion of splicing in HeLa-NE (Fig. 1A, transcript IIIa-U1,
compare lanes 5 and 10). IIIa splicing without the U1 en-
hancer was barely detectable (Fig. 1A, lane 10). Based on
results like this, we previously concluded [10] that U1 snRNP
binding downstream of the weak IIIa 3P splice site functions
as a splicing enhancer stimulating IIIa intron removal. Later
studies have shown that the SR protein ASF/SF2 can directly
bind to a 5P splice site [17]. We therefore re-investigated the
importance of U1 snRNP as the IIIa-U1 splicing enhancer
factor.
To characterize the factor causing activation of IIIa-U1
splicing, we fractionated HeLa-NE by ASP into three frac-
tions, the 40, 60 and 90 ASP. As shown in Fig. 1A, the 40
ASP, but not the 60 or 90 ASP, activated IIIa-U1 splicing
(lanes 3^5). Since most SR proteins are enriched in the 90
ASP fraction [12], this result argues against SR proteins as
the enhancer factor stimulating IIIa-U1 splicing. This result
was expected since we have previously demonstrated that SR
proteins functions as repressor, not activator proteins of IIIa
splicing [8,18]. None of the fractions was able to activate IIIa
splicing (lanes 7^9).
Based on our previous work [10], we predicted that 40 ASP
would be enriched in U1 snRNP. Western blot analysis, using
a monoclonal antibody speci¢c for the U1-70K protein, con-
¢rmed that U1 snRNP was indeed selectively enriched in 40
ASP (Fig. 1B). To further show that it was U1 snRNP that
was the enhancer factor, we used RNase H-oligonucleotide-
directed depletion to functionally inactivate U1 snRNA in 40
ASP. As shown in Fig. 1C, incubating 40 ASP with increasing
amounts of an U1 oligonucleotide during the RNase H treat-
ment abolished the stimulatory e¡ect of 40 ASP on IIIa-U1
splicing. In contrast, pre-treatment of 40 ASP with an U2-
Fig. 1. Enhancer-dependent splicing of the adenovirus IIIa pre-mRNA. A: 40 ASP activates IIIa-U1 but not IIIa splicing in splicing de¢cient
S100 extracts. HeLa-NE separated into three fractions (40, 60 and 90 ASP) by ASP was used to program splicing in splicing de¢cient S100 ex-
tracts. Ad-NE, a control showing IIIa splicing in nuclear extracts prepared from late adenovirus-infected cells [23]. B: Western blot analysis,
demonstrating that U1 snRNP is enriched in the 40 ASP fraction. C: Oligonucleotide directed RNase H cleavage of 40 ASP showing that an
intact U1 snRNA is required for the enhancer activity of 40 ASP. Mock, extract treated with RNase H in the absence of oligonucleotide. In A
and C, the structure of transcripts is shown at the top with the position of pre-mRNA and splicing products marked on the side of each auto-
radiogram. bU1 denotes the presence of an U1 enhancer (the adenovirus major late ¢rst intron 5P splice site [10]).
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speci¢c oligonucleotide had no e¡ect on the 40 ASP activation
of splicing. Collectively, these results demonstrate that U1
snRNP, with an intact U1 snRNA, is required for the en-
hancer activity of 40 ASP on IIIa-U1 splicing.
3.2. 52,55K intron splicing requires a downstream splicing
enhancer
In contrast to IIIa splicing which is strongly activated by an
U1 enhancer, splicing of the 52,55K intron is only marginally
activated by an U1 enhancer in HeLa-NE (Fig. 2B, lanes 1
and 2). As shown in Fig. 2C, addition of 40 ASP to S100
extracts only activated 52,55K-U1 splicing. RNase H oligonu-
cleotide depletion of U1 snRNA abolished the stimulatory
e¡ect of 40 ASP on 52,55K-U1 splicing (data not shown).
In contrast, addition of puri¢ed HeLa SR proteins activated
both 52,55K-U1 and 52,55K splicing in a S100 complementa-
tion assay (Fig. 2C). SR proteins function as splicing enhancer
proteins typically by binding to exonic enhancer elements (re-
viewed in [1,2]). To determine whether 52,55K splicing re-
quires a downstream splicing enhancer, we replaced the
52,55K second exon with a L-globin sequence that we previ-
ously have shown does not bind any of the classical SR pro-
teins [8], thus, creating transcript 52,55K(E3) (Fig. 2A). Re-
markably, this transcript was completely inactive in splicing in
HeLa-NE (Fig. 2B, lane 4). This result strongly suggests that
splicing of a ‘strong’ constitutively active intron also requires
Fig. 2. A downstream splicing enhancer is essential for 52,55K splicing. A: The structure of 52,55K pre-mRNAs used in B and C is graphically
depicted. bU1 denotes the presence of an U1 enhancer (the adenovirus major late ¢rst intron 5P splice site [10]). 3RE and 2ASF are two types
of exonic SR binding splicing enhancer sequences. E3 (thin line), an enhancer minus sequence that does not bind SR proteins [8]. B: Redun-
dant function of a SR enhancer and an U1 enhancer in activating 52,55K splicing. The transcript shown in A was used to program splicing in
HeLa-NE. C: SR proteins and 40 ASP di¡er in their capacity to activate 52,55K+/3an U1 enhancer in S100 extracts.
Fig. 3. A downstream splicing enhancer is required for Ftz splicing
in HeLa-NE. Replacement of the Ftz second exon with an enhancer
minus sequence (Ftz(E3)) that does not bind SR proteins [8] abol-
ishes Ftz splicing in vitro (lanes 5^8). Appending an U1 enhancer
to the Ftz(E3) pre-mRNA restored Ftz splicing (lanes 9^12).
FEBS 21982 10-5-99
B.-G. Yue, G. Akusja«rvi/FEBS Letters 451 (1999) 10^1412
a downstream splicing enhancer for activity. Importantly, ap-
pending an U1 enhancer to the 52,55K(E3) transcript re-
gained its splicing activity in HeLa-NE (52,55K(E3)-U1:
Fig. 2B, lane 5) or in S100 extracts supplemented with 40
ASP (data not shown). This result is signi¢cant, because it
suggests that the L-globin sequence replacing the 52,55K sec-
ond exon was not inhibitory for splicing. More likely, it was
non-functional, because it does not have the capacity to bind
any splicing enhancer factors. In agreement with this hypoth-
esis, appending a characterized ASF/SF2 splicing enhancer [9],
or the 3RE, which binds all of the classical SR proteins [8],
e¡ectively restored 52,55K intron splicing (Fig. 2B, lanes 3
and 6).
Collectively, these results demonstrate that a downstream
splicing enhancer (SR or U1 enhancer) is obligatory for splic-
ing the ‘strong’ constitutively active 52,55K intron.
3.3. Drosophila Ftz intron splicing requires a downstream
splicing enhancer
To demonstrate that the requirement for a downstream
splicing enhancer was not unique to 52,55K splicing, we tested
the importance of the Drosophila Ftz second exon for its splic-
ing activity. As shown in Fig. 3, Ftz intron splicing is very
e⁄cient with a conversion of almost 50% of input RNA (lane
1) to spliced product (lane 4) after 90 min of incubation.
Substituting the Ftz second exon with the L-globin enhancer
minus sequence used above (Fig. 2) completely abolished Ftz
intron splicing (transcript Ftz(E3)). Appending an U1 en-
hancer to the Ftz(E3) transcript restored Ftz intron splicing,
to wild-type levels (transcript Ftz(E3)-U1). Again, demon-
strating that the L-globin sequence did not function as an
inhibitory sequence for splicing. This result strengthens our
model that a downstream splicing enhancer is obligatory
also for splicing of ‘strong’ constitutively active introns in
HeLa-NE.
We note that the Ftz(E3) pre-mRNA was rapidly degraded
if not spliced (Fig. 3, lanes 5^8), suggesting that the Ftz intron
contains a destabilizing sequence that causes degradation of
the pre-mRNA if it is not committed to splicing.
3.4. An U1 enhancer is more versatile compared to an
SR enhancer
Neither an U1 enhancer nor a SR enhancer is functional in
S100 extracts (Figs. 2C and 4), suggesting that S100 extracts
contain sub-optimal concentrations of both SR proteins and
U1 snRNP. This allowed us to design an experiment to test
the importance of a respective enhancer for upstream intron
splicing. As shown in Fig. 4, addition of 40 ASP activated
52,55K(E3)-U1 splicing (lane 6), but not 52,55(3RE) splicing
(lane 3). In contrast, supplementing S100 extracts with SR
proteins activated both 52,55K(3RE) and 52,55K(E3)-U1
splicing (lanes 2 and 5). We interpret this result to indicate
that an U1 enhancer is more e¡ective compared to a SR
enhancer. It is activated both by SR proteins and U1 snRNP.
In contrast, an SR enhancer is only activated by SR proteins.
Based on this observation, and general considerations con-
cerning the splice site de¢nition (see Section 4), we propose
that U1 enhancers are the prototypical enhancer element ac-
tivating splicing of constitutively active introns.
4. Discussion
Previous studies have shown that splicing enhancer ele-
ments are important regulatory elements controlling spliceo-
some assembly at weak-regulated 3P splice sites containing
sub-optimal splicing signals (reviewed in [1^3]). Here, we ex-
tend these studies by demonstrating that a downstream splic-
ing enhancer also is obligatory for in vitro splicing of ‘strong’
constitutively active introns, here exempli¢ed by the adenovi-
rus 52,55K and the Drosophila Ftz introns. We further show
that two types of elements function as splicing enhancers in
cis-splicing. Thus, a downstream 5P splice site, which binds U1
snRNP (U1 enhancer), or an exonic SR protein binding ele-
ment (SR enhancer) can individually stimulate upstream in-
tron splicing in vitro.
The mechanism of 3P and 5P splice site recognition across an
exon operates with minimal sequence information in higher
eukaryotes. Thus, multiple weak interactions between U2AF/
U2 snRNP binding to the 3P splice site, SR proteins binding
to exonic splicing enhancer elements and U1 snRNP interact-
ing with the downstream 5P splice site have been proposed to
be required for recognition of an exon in a pre-mRNA (re-
viewed in [1,2,3]). Our results suggest that U1 enhancers are
more signi¢cant, compared to SR enhancers, as splicing acti-
vator elements. Two lines of evidence support this conclusion.
First, e⁄cient splice site pairing occurs in the complete ab-
sence of an exonic splicing enhancer element (the enhancer
minus (E3) transcripts, Figs. 2B, 3 and 4). Second, we show
that an U1 enhancer is capable of activating splicing in S100
extracts under conditions where a SR enhancer is non-func-
tional (Fig. 4). These ¢ndings are important since they suggest
that U1 snRNP binding to the downstream 5P splice site may
in most cases su⁄ce as a splicing enhancer for upstream in-
tron removal. Thus, there appears to be no absolute require-
ment for SR enhancers in splicing of internal exons in verte-
brate genes. Such a ¢nding may be relevant since usage of an
exonic SR enhancer requires co-evolution of the enhancer and
Fig. 4. An U1 enhancer is more e¡ective compared to a SR en-
hancer in activating 52,55K splicing in vitro. Supplementing S100
extracts with SR proteins or 40 ASP, which is enriched in U1
snRNP, shows that an U1 enhancer, but not a SR enhancer, is acti-
vated by both enhancer factors. The structure of the pre-mRNAs
used is depicted at the top of the ¢gure and the position of pre-
mRNAs and splicing products between the two autoradiograms.
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the amino acid sequence encoded by the exon. We propose
that U1 enhancers are the prototypical splicing enhancer used
in constitutive splicing. SR enhancers may serve their primary
function as elements regulating processing of introns contain-
ing ‘weak’ splicing signals and unusual exons which are to
long to allow direct pairing of splice sites across the exon
(see [4]).
Current models suggest that SR proteins stabilize U2AF
interaction with U1 snRNP by making simultaneous contact
with U2AF35K and U1-70K (reviewed in [1,2]). The surpris-
ing ¢nding that U1 snRNP activates splicing in S100 extracts
(Figs. 1C, 2C and 4), which are depleted of functional con-
centrations of SR proteins [11], would, at a ¢rst glance, argue
against this hypothesis by suggesting that SR proteins are
dispensable for the activity of an U1 enhancer. However,
splicing de¢cient S100 extracts contain low amounts of SR
proteins (data not shown), below the threshold concentration
required to activate constitutive splicing (Figs. 2C and 4).
Thus, an alternative explanation would be that the RNA
binding a⁄nity of SR protein is functionally lower compared
to the concentrations required for protein-protein interaction
between SR proteins and U1 snRNP. Therefore, the sub-op-
timal concentrations of functional SR proteins in S100 ex-
tracts might be su⁄cient to activate splicing using an U1
enhancer, but fail to activate splicing through an SR en-
hancer. Also, SR proteins collaborate with U1 snRNP to
form stable interaction with a 5P splice site [19,20]. Thus,
addition of an excess of U1 snRNP to S100 extracts might
activate an U1 enhancer by e⁄ciently recruiting the low
amount of SR proteins in the extract to the 5P splice site.
Similarly, addition of an excess of SR proteins to S100 ex-
tracts might help to recruit the sub-optimal amount of U1
snRNP in the extract to an U1 enhancer. Such a model would
explain why SR proteins activate an U1 enhancer (Fig. 2C).
Although this hypothesis is attractive, we have not been able
to experimentally prove that the sub-optimal amounts of SR
proteins present in S100 extracts are e⁄ciently recruited to an
U1 enhancer (data not shown).
Our results lend further support to the model that splice
sites are initially paired by splicing factor interaction across
the exon [4]. Thus, supplementing S100 extracts with a frac-
tion enriched in U1 snRNP stimulates 3P to 5P splice site
interaction across the exon, but did not stimulate 5P to 3P
splice site interaction across the intron (Figs. 1A, 2C and 4).
The observation that a downstream 5P splice site activates
upstream intron splicing in the absence of an exonic SR en-
hancer further emphasizes the signi¢cance of splice site pair-
ing across the exon, through factor interaction directly with
the 3P and 5P splice sites. We also show that splicing of the
Drosophila Ftz intron requires a downstream splicing en-
hancer (Fig. 3), i.e. splice site de¢nition according to the
exon de¢nition model. At a ¢rst glance, this observation ap-
pears to contradict the proposal that introns, not exons, con-
stitute the unit for splice site pairing in lower eukaryotes (re-
viewed in [5]). However, Drosophila appears to be
intermediate, with some genes using exons as the unit for
splice site de¢nition [5,21]. In fact, the Ftz intron has been
suggested to exhibit properties similar to that of introns of
higher eukaryotes (discussed in [22]). Our data show that Ftz
intron splicing operates via exon de¢nition in HeLa-NE
(Fig. 3).
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